Shares of IQVIA Holdings Inc. (IQV) have risen 15% over the past year, outperforming the 12.1% growth of the industry it belongs to. The company has an expected long-term (three to five years) EPS growth rate of 10.9%. Its earnings for 2024 and 2025 are anticipated to grow 8.4% and 12.5%, respectively, year over year. Factors That Bode Well IQV's extensive data collection, comprising more than one billion patient records and 61 petabytes of proprietary data from 150,000 suppliers, sets it apart and creates ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-35907 ______ ...

IQVIA Holdings Analytics Inc. (IQV) has reported impressive first-quarter 2024 results, wherein earnings and revenues beat the Zacks Consensus Estimate.Adjusted earnings (excluding 98 cents from non-recurring items) were $2.5 per share, beating the Zacks Consensus Estimate by 2.8% and increasing 3.7% from the year-ago reported figure. Total revenues of $3.7 billion surpassed the consensus estimate by 1.2% and grew 2.3% from the year-ago quarter.The IQV stock has gained 25.5% over the past year, outperformin ...

100% 50% 75% 25% 100% 50% 75% 25% This presentation should be viewed in conjunction with IQVIA's Q1 2024 earnings call In all cases where historical results are presented or past performance is described, we note that past performance is not a reliable indicator of future results and performance. Legal IQVIA Template (V2.1.0) 1 st Quarter Balance Sheet and Cash Flow Items and Metrics Dollars are at actual foreign exchange rates. (1) Calculated using last twelve months Adjusted EBITDA. (2) See reconciliation ...

IQVIA Holdings (IQV) came out with quarterly earnings of $2.54 per share, beating the Zacks Consensus Estimate of $2.47 per share. This compares to earnings of $2.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.83%. A quarter ago, it was expected that this clinical testing company would post earnings of $2.82 per share when it actually produced earnings of $2.84, delivering a surprise of 0.71%.Over the last four quarters, ...

First-Quarter 2024 Operating Results Revenue for the first quarter of $3,737 million increased 2.3 percent on a reported basis and 2.9 percent at constant currency, compared to the first quarter of 2023. Technology & Analytics Solutions (TAS) revenue of $1,453 million increased 0.6 percent on a reported basis and 1.0 percent at constant currency. Research & Development Solutions (R&DS) revenue of $2,095 million increased 3.4 percent on a reported basis and 3.8 percent at constant currency. Excluding the imp ...

IQVIA Holdings, Inc. (IQV) is scheduled to release its first-quarter 2024 results on May 2, before market open.IQV has an impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in each of the four trailing quarters, the average surprise being 1.5%.Q1 ExpectationsThe Zacks Consensus Estimate for the top line is currently pegged at $3.7 billion, up 1.1% from the year-ago quarter. The growth in revenues is likely to have been due to an uptick in demand of clients, strategic acquisi ...

Wall Street analysts expect IQVIA Holdings (IQV) to post quarterly earnings of $2.47 per share in its upcoming report, which indicates a year-over-year increase of 0.8%. Revenues are expected to be $3.69 billion, up 1.1% from the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Ahead of a company's earnings disclosure, it is cr ...

IQVIA Holdings (IQV) stock has gained 7.5%, outperforming 2.5% and 6.1% growth of the industry it belongs to and the Zacks S&P 500 Composite in the past three months, respectively.IQV has an expected long-term (three to five years) EPS growth rate of 10.2%. The company’s earnings for 2024 and 2025 are anticipated to grow 8.6% and 13% year over year, respectively. Revenues are expected to increase 3.5% in 2024 and 7.9% in 2025.Factors That Auger WellIQVIA’s robust capabilities place it strongly in the life s ...

Financial Performance - The company reported a significant increase in revenue, reaching $X billion, representing a Y% growth compared to the previous year[7]. - User data showed an increase in active users, with a total of Z million users, marking a W% increase year-over-year[7]. - The company provided an optimistic outlook for the next fiscal year, projecting revenue growth of A% to B%[12]. Product Development and Market Expansion - New product launches are expected to contribute an additional $C million in revenue, with anticipated market expansion in D regions[7]. - The company is investing in R&D, allocating $E million towards the development of new technologies and services[7]. - Market expansion efforts include strategic partnerships aimed at increasing market share by F% in the next year[7]. - The company is exploring potential acquisitions to enhance its service offerings and expand its client base[7]. Operational Efficiency and Cost Management - The management highlighted a focus on improving operational efficiency, targeting a G% reduction in costs over the next fiscal year[7]. Risk Management - The company is facing risks related to regulatory changes, which could impact its market position and operational capabilities[13]. - Forward-looking statements indicate that the company is prepared to navigate potential disruptions, including economic fluctuations and geopolitical tensions[14]. Market Research and Data Reliability - The company relies on third-party surveys and market research for healthcare industry data, which may not be independently verified[18]. - IQVIA Market Prognosis provides five-year pharmaceutical market forecasts at national, regional, and global levels[18]. - The company maintains databases and produces market analyses widely referenced in the healthcare industry[18]. - Information from the IQVIA Institute for Human Data Science is publicly available and based on internal research[18]. - Estimates and assumptions regarding market data involve risks and uncertainties that could lead to materially different results[18].